Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2

Status

Recruiting 3Unknown 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 8

Study Type

Interventional 8

Sponsor

Cancer Type

Dermatologic 8Sarcoma 1

Conditions

Melanoma 4Carcinoma, Basal Cell 4Sarcoma, Kaposi 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
INDUSTRY × daromun × Dermatologic × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT07227870 2026-03-09

L19IL2/TNF in Patients With Basal Cell Carcinoma

Philogen S.p.A.

Phase 2 Not yet recruiting
92 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT03567889 2025-12-17

NeoDREAM

Philogen S.p.A.

Phase 3 Recruiting
186 enrolled
Dermatologic

Melanoma

NCT06284590 2024-10-26

INTACT/MeRCI

Philogen S.p.A.

Phase 2 Recruiting
162 enrolled
Dermatologic

Melanoma

NCT02938299 2024-09-19

Pivotal

Philogen S.p.A.

Phase 3 Active not recruiting
214 enrolled
Dermatologic

Melanoma

NCT04362722 2023-10-10

DUNCAN

Philogen S.p.A.

Phase 2 Unknown
40 enrolled
Dermatologic

Carcinoma, Carcinoma, Basal Cell

NCT05329792 2023-10-06

IntriNSiC

Philogen S.p.A.

Phase 2 Unknown
70 enrolled
DermatologicSarcoma

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Sarcoma, Kaposi, Carcinoma, Merkel Cell

NCT02076633 2015-05-27

Intratumoral Administration of L19IL2/L19TNF

Philogen S.p.A.

Phase 2 Completed
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡